296 related articles for article (PubMed ID: 23541251)
21. Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia.
Collins CD; Ellis JJ; Kaul DR
Am J Health Syst Pharm; 2008 Dec; 65(23):2237-43. PubMed ID: 19020192
[TBL] [Abstract][Full Text] [Related]
22. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
[TBL] [Abstract][Full Text] [Related]
23. Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis.
Dranitsaris G; Khoury H
Support Care Cancer; 2011 Nov; 19(11):1807-13. PubMed ID: 20972589
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
Sohn HS; Lee TJ; Kim J; Kim D
Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
[TBL] [Abstract][Full Text] [Related]
25. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants.
Mauskopf J; Chirila C; Graham J; Gersten ID; Leather H; Maziarz RT; Baden LR; Bolaños-Meade J; Brown JM; Walsh TJ; Horowitz MH; Kurtzberg J; Marr KA; Wingard JR
Am J Health Syst Pharm; 2013 Sep; 70(17):1518-27. PubMed ID: 23943184
[TBL] [Abstract][Full Text] [Related]
26. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
27. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
[TBL] [Abstract][Full Text] [Related]
28. Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system.
Michallet M; Gangneux JP; Lafuma A; Herbrecht R; Ribaud P; Caillot D; Dupont B; Moreau P; Berger P; O'Sullivan AK
J Med Econ; 2011; 14(1):28-35. PubMed ID: 21175376
[TBL] [Abstract][Full Text] [Related]
29. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
[TBL] [Abstract][Full Text] [Related]
30. Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands.
Jansen JP; O'Sullivan AK; Lugtenburg E; Span LF; Janssen JJ; Stam WB
Ann Hematol; 2010 Sep; 89(9):919-26. PubMed ID: 20383504
[TBL] [Abstract][Full Text] [Related]
31. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
Oren I; Rowe JM; Sprecher H; Tamir A; Benyamini N; Akria L; Gorelik A; Dally N; Zuckerman T; Haddad N; Fineman R; Dann EJ
Bone Marrow Transplant; 2006 Jul; 38(2):127-34. PubMed ID: 16751782
[TBL] [Abstract][Full Text] [Related]
32. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
Ziakas PD; Kourbeti IS; Mylonakis E
Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
[TBL] [Abstract][Full Text] [Related]
33. Comparative survival and cost of antifungal therapy: posaconazole versus standard antifungals in the treatment of refractory invasive aspergillosis.
Herbrecht R; Rajagopalan S; Danna R; Papadopoulos G
Curr Med Res Opin; 2010 Oct; 26(10):2457-64. PubMed ID: 20822354
[TBL] [Abstract][Full Text] [Related]
34. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation.
Chaftari AM; Hachem RY; Ramos E; Kassis C; Campo M; Jiang Y; Prince RA; Wang W; Raad II
Transplantation; 2012 Aug; 94(3):302-8. PubMed ID: 22814329
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients.
Liu F; Wu T; Wang JB; Cao XY; Yin YM; Zhao YL; Lu DP
Transpl Infect Dis; 2013 Jun; 15(3):243-50. PubMed ID: 23496156
[TBL] [Abstract][Full Text] [Related]
36. Comparison of long-term and short-term administration of itraconazole for primary antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: a multicenter, randomized, open-label trial.
Lin R; Xu X; Li Y; Sun J; Fan Z; Jiang Q; Huang F; Zhou H; Nie D; Guo Z; Mao Y; Xiao Y; Liu Q
Transpl Infect Dis; 2014 Apr; 16(2):286-94. PubMed ID: 24593273
[TBL] [Abstract][Full Text] [Related]
37. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation.
Sánchez-Ortega I; Patiño B; Arnan M; Peralta T; Parody R; Gudiol C; Encuentra M; Fernández de Sevilla A; Duarte RF
Bone Marrow Transplant; 2011 May; 46(5):733-9. PubMed ID: 20697369
[TBL] [Abstract][Full Text] [Related]
38. SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy.
Busca A; Lessi F; Verga L; Candoni A; Cattaneo C; Cesaro S; Dragonetti G; Delia M; De Luca A; Guglielmi G; Tumbarello M; Martino G; Nadali G; Fanci R; Picardi M; Potenza L; Nosari A; Aversa F; Pagano L;
Leuk Lymphoma; 2017 Dec; 58(12):2859-2864. PubMed ID: 28508692
[TBL] [Abstract][Full Text] [Related]
39. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
[TBL] [Abstract][Full Text] [Related]
40. [Cost benefit analysis for prophylactic use of itraconazole versus fluconazole after hematopoietic stem cell transplantation].
Ota S; Wada A; Kosugi M; Matsuoka S; Asanuma S; Fujii S; Noguchi S; Nakata M; Imai K; Hirano T; Kobayashi N; Ogasawara M; Kiyama Y; Kasai M
Rinsho Ketsueki; 2010 Jan; 51(1):63-8. PubMed ID: 20134142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
